Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD
40.03
+0.31 (0.78%)
Apr 23, 2025, 3:53 PM EDT
17.67%
Market Cap 17.36B
Revenue (ttm) 10.38B
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend 0.53 (1.33%)
Ex-Dividend Date Apr 22, 2025
Volume 3,124
Average Volume 50,971
Open 39.99
Previous Close 39.72
Day's Range 40.02 - 40.65
52-Week Range 32.48 - 49.81
Beta n/a
RSI 46.23
Earnings Date Aug 7, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,049
Stock Exchange OTCMKTS
Ticker Symbol SDZNY
Full Company Profile

Financial Performance

Financial Statements

News

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...

9 days ago - GlobeNewsWire

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...

9 days ago - Benzinga

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated

9 days ago - GlobeNewsWire

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News

10 days ago - GuruFocus

Switzerland's Sandoz files antitrust lawsuit against Amgen in US

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...

10 days ago - Reuters

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...

10 days ago - GlobeNewsWire

Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions

La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...

19 days ago - elEconomista.es

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...

23 days ago - GlobeNewsWire

Sandoz signs landmark supply and manufacturing agreement

BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...

5 weeks ago - GlobeNewsWire

Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE

BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...

5 weeks ago - Benzinga

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives

7 weeks ago - GuruFocus

US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

7 weeks ago - Financial Post

Health Care Roundup: Market Talk

Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.

7 weeks ago - The Wall Street Journal

Sandoz reports strong FY 2024 results and Q4 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2....

7 weeks ago - GlobeNewsWire

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upf...

7 weeks ago - PRNewsWire

Sandoz family foundation offers $3 billion worth of Novartis shares

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil...

2 months ago - Reuters

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...

2 months ago - Benzinga

MS patients suffer side-effects after NHS England switches to cheaper drug

Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money ‘It was awful for me’: one MS patient shares her experience with Tyruko Scores of peopl...

2 months ago - The Guardian

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars...

2 months ago - GlobeNewsWire

Francisco Ballester to retire; Peter Stenico appointed President Region International

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, cu...

2 months ago - GlobeNewsWire